 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In the second quarter of FY24, the Pharma stocks saw strong revenue growth of 14.3% year-over-year and 1.7% quarter-over-quarter

Nifty Pharma scales record highs, rises in 14 out of 17 straight sessions

Divi's Laboratories has received a Goods and Service Tax (GST) demand notice of ₹82 crore. The company does not expect the order to have any material financial impact on it, according to a filing.

Divi's Laboratories gets GST demand notice of ₹164 crore

Divi's Laboratories gets GST demand notice of ₹82 crore

Prabhudas Lilladher recommended reduce rating on Divi's Laboratories with a target price of Rs 3150 in its research report dated October 06, 2023.

Reduce Divi's Laboratories; target of Rs 3150: Prabhudas Lilladher

Divis Labs Consolidated September 2023 Net Sales at Rs 1,909.00 crore, up 2.94% Y-o-Y

Divis Labs Standalone September 2023 Net Sales at Rs 1,868.00 crore, up 2.45% Y-o-Y

Divi's Laboratories reported an on year slump in its net profit and operating margin while revenue growth remained muted in Q2.

Divi's Labs fails to cheer up brokerages with weak Q2 results, sharp margin contraction

A poll of eight brokerages collated by Moneycontrol had pegged net profit at Rs 423 crore and revenue at Rs 1,913.2 crore

Divi's Lab Q2 results: Net profit down 29% to Rs 348 crore, misses estimates

A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi's Labs

Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix

The markets were supported by domestic funds and retail investors that were more comfortable with the valuations of small and mid-cap stocks.

Why blue-chips are lagging behind as mid- and small-cap stocks rally

Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. It also provides manufacturing of generic APIs, nutraceutical ingredients, and custom synthesis for big pharma. The company was founded by Murali Krishna Prasad Divi on October 12, 1990 and is headquartered in Hyderabad, India.

Watchers	2,916
52-Wk Low	2,730.00
52-Wk High	3,934.70

Market Cap	1.01T
Volume (M)	318,936.00
52-Wk High	3,934.70
52-Wk Low	2,730.00

DIVISLAB.NSE Divi`s Laboratories Ltd.

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community